We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves Par's ANDA For Generic Questran
FDA Approves Par's ANDA For Generic Questran
September 6, 2005
Par Pharmaceutical has received final approval from the FDA for its abbreviated new drug applications for cholestyramine for oral suspension, 4 g resin/9 g powder and cholestyramine for oral suspension, (light), 4 g resin/5 g powder.
